78994-24-8 ((±)-反-1-[2-[4-(3,4-二氢-7-甲氧基-2,2-二甲基-3-苯基-2H-1-苯并吡喃-4-基)苯氧基]乙基]吡咯烷,(- )-1-(2-(p-(trans-7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine)

奥美昔芬;森可曼;(±)-反-1-[2-[4-(3,4-二氢-7-甲氧基-2,2-二甲基-3-苯基-2H-1-苯并吡喃-4-基)苯氧基]乙基]吡咯烷;

(- )-1-(2-(p-(trans-7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine;1-(2-{4-[(3S,4S)-7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-c hromen-4-yl]phenoxy}ethyl)pyrrolidine;(+-)-1-(2-(p-(trans-7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine;Ormeloxifene [INN];UNII-44AXY5VE90;(-)-1-(2-(4-((3R,4R)-7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine;trans-Centchroman;LEVORMELOXIFENE [WHO-DD];SCHEMBL107914;DTXSID301317017;1-(2-(4-((3R,4R)-7-methoxy-2,2-dimethyl-3-phenylchroman-4-yl)phenoxy)ethyl)pyrrolidine;(+/-)-1-(2-(P-(TRANS-7-METHOXY-2,2-DIMETHYL-3-PHENYL-4-CHROMANYL)PHENOXY)ETHYL)PYRROLIDINE;9512UKZ352;NNC-46-0020;1-(2-(p-(trans-7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine;trans-1-(2-(p-(7-Methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine;3,4-trans-2,2-Dimethyl-3-phenyl-4-(p-(beta-pyrrolidinoethoxy)phenyl)-7-methoxychroman;DB13310;Pyrrolidine, 1-(2-(4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy)ethyl)-, trans-;trans-2,2-Dimethyl-3-phenyl-4-(p-(beta-pyrrolidinoethoxy)phenyl)-7-methoxychroman;Ormeloxifene;Centron;NS00126803;BDBM50219398;ORMELOXIFENE [WHO-DD];ORMELOXIFENE [MART.];L-CentchroMan;Saheli;Pyrrolidine, 1-(2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)-, trans-;Choice 7;3,4-Trans-2,2-dimethyl-3-phenyl-4-(p-(beta-pyrrolidinoethoxy)-phenyl)-7-methoxychroman;BRN 6075092;(-)-centchroman;CENTCHROMAN (-)-FORM [MI];Compound 67/20;UNII-9512UKZ352;CHEMBL301327;Q6535824;Levormeloxifene [INN];78994-24-8;Centchroman-l;CENTCHROMAN [MI];Levormeloxifene;1-[2-[4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine;6720-CDRI;78994-23-7;44AXY5VE90;Centchroman (-)-form;AKOS032953987;Pyrrolidine, 1-(2-(4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl)phenoxy)ethyl)-, (3R-trans)-;CENTCHROMAN;

XZEUAXYWNKYKPL-WDYNHAJCSA-N

1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1

O1C2C=C(C=CC=2[C@@H](C2C=CC(=CC=2)OCCN2CCCC2)[C@H](C2C=CC=CC=2)C1(C)C)OC

非甾体结构的女用口服避孕药,一周只需服用一次。

15g2,2-二甲基-4-(对羟基苯基)-7-甲氧基-3-苯基色烯[2,2-Dimethyl-4-(p-hydrocyphenyl)-7-methoxy-3-phenylchromene]溶于250ml四氢呋喃,加入7.5g 5%钯-炭催化剂,在7MPa的氢压和70℃下氢化12he.滤去催化剂,真空浓缩至于。剩余物用苯-石油醚(30～60℃)重结晶,得顺-2,2-二甲基-4-(对羟基苯基)-7-甲氧基-3-苯基色满,熔点174～177℃。 上述得到的色满衍生物(50g,0.13mo1)和****水溶液(13.9g溶于40ml水)加到250ml异丙醇中,搅拌15min后,加入23.5g(0.139mo1)N-(2-氯乙基)吡咯烷盐酸盐,在50℃搅拌4h。冷却,用500ml水稀释后,用乙醚提取2次。提取液水洗后,用1mol/L盐酸水溶液提取数次。该酸性提取液用50%****碱化后,即得白色固体的顺式森可曼,熔点117.5～119℃。 该顺式产品(9.0g)和无水二甲亚砜(100...